Literature DB >> 23973868

Prognostic relevance of papillary muscle infarction in reperfused infarction as visualized by cardiovascular magnetic resonance.

Ingo Eitel1, Dörthe Gehmlich, Omran Amer, Jochen Wöhrle, Sebastian Kerber, Bernward Lauer, Matthias Pauschinger, Johannes Schwab, Ralf Birkemeyer, Rainer Zimmermann, Meinhard Mende, Suzanne de Waha, Steffen Desch, Matthias Gutberlet, Gerhard Schuler, Holger Thiele.   

Abstract

BACKGROUND: The prognostic significance of papillary muscle infarction (PapMI) on hard clinical outcomes has not been investigated in patients with reperfused ST-segment-elevation myocardial infarction. Noninvasive investigation by gadolinium-enhanced cardiac MRI enables the detection of PapMI with high spatial resolution. The aim of our study was (1) to assess the incidence, determinants, and clinical characteristics of PapMI in a large multicenter cohort of patients with ST-segment-elevation myocardial infarction and (2) to assess the prognostic significance of PapMI at 1-year follow-up. METHODS AND
RESULTS: We enrolled 738 patients with ST-segment-elevation myocardial infarction reperfused by primary angioplasty (<12 hours after symptom onset) in this cardiac MRI study at 8 centers. Cardiac MRI was completed within 1 week after infarction using a standardized protocol. Central core laboratory-masked analyses for the presence of PapMI were performed. The primary clinical end point of the study was the occurrence of major adverse cardiac events. PapMIs were detected in 104 patients (14%). The presence of PapMI was associated with larger infarcts (P<0.001), less myocardial salvage (P<0.001), impaired left ventricular function (P<0.001), and more pronounced reperfusion injury (P=0.02). Patients with PapMI had a significantly higher mortality (8 [7.7%] versus 12 [1.9%]) and major adverse cardiac events (21 [20.2%] versus 31 [4.9%]) rate at 12-month follow-up (P<0.001, respectively). PapMI was identified as a significant independent predictor of major adverse cardiac events (hazard ratio, 4.41 [confidence interval, 2.54-7.68]; P<0.001).
CONCLUSIONS: The presence of PapMI is associated with decreased myocardial salvage, larger infarcts, and more pronounced reperfusion injury with subsequent significantly increased major adverse cardiac event rates. Consequently, our data underscore the importance of PapMI as a marker of poor outcome in patients with ST-segment-elevation myocardial infarction.

Entities:  

Keywords:  magnetic resonance imaging; myocardial infarction; papillary muscles; prognosis

Mesh:

Substances:

Year:  2013        PMID: 23973868     DOI: 10.1161/CIRCIMAGING.113.000411

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  10 in total

1.  Impact of posteromedial papillary muscle infarction on mitral regurgitation during ST-segment elevation myocardial infarction.

Authors:  Gert Klug; Hans-Josef Feistritzer; Sebastian J Reinstadler; Martin Reindl; Christina Tiller; Magdalena Holzknecht; Agnes Mayr; Silvana Müller; Axel Bauer; Bernhard Metzler
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-09       Impact factor: 2.357

2.  Predictors of moderate to severe ischemic mitral regurgitation after myocardial infarction: a cardiac magnetic resonance study.

Authors:  Chen Zhang; Lei Zhao; Enjun Zhu; Paul Schoenhagen; Jie Tian; Yong-Qiang Lai; Xiaohai Ma
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

Review 3.  Utility of cardiac magnetic resonance for evaluation of mitral regurgitation prior to mitral valve surgery.

Authors:  Neil K Mehta; Jiwon Kim; Jonathan Y Siden; Sara Rodriguez-Diego; Javid Alakbarli; Antonino Di Franco; Jonathan W Weinsaft
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

4.  Chronic ischemic mitral regurgitation and papillary muscle infarction detected by late gadolinium-enhanced cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction.

Authors:  Wobbe Bouma; Hendrik M Willemsen; Chris P H Lexis; Niek H Prakken; Erik Lipsic; Dirk J van Veldhuisen; Massimo A Mariani; Pim van der Harst; Iwan C C van der Horst
Journal:  Clin Res Cardiol       Date:  2016-06-08       Impact factor: 5.460

5.  Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar.

Authors:  Rohin Francis; Peter Kellman; Tushar Kotecha; Andrea Baggiano; Karl Norrington; Ana Martinez-Naharro; Sabrina Nordin; Daniel S Knight; Roby D Rakhit; Tim Lockie; Philip N Hawkins; James C Moon; Derek J Hausenloy; Hui Xue; Michael S Hansen; Marianna Fontana
Journal:  J Cardiovasc Magn Reson       Date:  2017-11-21       Impact factor: 5.364

Review 6.  Magnetic resonance imaging of the papillary muscles of the left ventricle: normal anatomy, variants, and abnormalities.

Authors:  Prabhakar Rajiah; Nicholas Lim Fulton; Michael Bolen
Journal:  Insights Imaging       Date:  2019-08-19

7.  Potential molecular mechanism of ACE gene at different time points in STEMI patients based on genome-wide microarray dataset.

Authors:  Yao-Zong Guan; Rui-Xing Yin; Peng-Fei Zheng; Guo-Xiong Deng; Chun-Xiao Liu; Bi-Liu Wei
Journal:  Lipids Health Dis       Date:  2019-10-23       Impact factor: 3.876

8.  Prognostic relevance and clinical features of papillary muscle infarction with mitral regurgitation in patients with ST segment elevation myocardial infarction.

Authors:  Dazhou Lei; Jun Xie; Qing Dai; Yinhao Huang; Xuan Wei; Dan Mu; Xue Bao; Jianhui Li; Biao Xu
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

Review 9.  Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.

Authors:  Stefan Frantz; Moritz Jens Hundertmark; Jeanette Schulz-Menger; Frank Michael Bengel; Johann Bauersachs
Journal:  Eur Heart J       Date:  2022-07-14       Impact factor: 35.855

Review 10.  Role of cardiovascular magnetic resonance in acute coronary syndrome.

Authors:  Jan Bogaert; Ingo Eitel
Journal:  Glob Cardiol Sci Pract       Date:  2015-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.